Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
1 finding from 1 review
Quality of life · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
1 finding from 1 review
OR 4
3 participants
GRADE not reported
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status at day 28 (data only available for clinical status worsened on day 7) · individuals with moderate or severe COVID‐19
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
1 finding from 1 review
RR 0.85 [0.58, 1.23]
Studies not reported
Very low
Improvement of clinical status · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in improvement of clinical status (number of people discharged from… compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 1.02 [0.97, 1.08]
Studies not reported
Moderate
Quality of life · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all grades · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.98 [0.81, 1.18]
Studies not reported
Low
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 4.09 [1.39, 12.01]
Studies not reported
Moderate
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
All‐cause mortality (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status (expressed as new need for IMV, admission to ICU, or death by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in worsening of clinical status (expressed as new need for IMV,… compared with saline placebo (low certainty).
1 finding from 1 review
Presence of dry socket · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
1 finding from 1 review
Reduction in level of contamination by particles >5 um (droplets) at <2 m from patient's oral cavity · Dental patients undergoing aerosol-generating procedures (AGPs) and the dental healthcare providers treating them
It is very uncertain whether povidone iodine changes reduction in level of contamination by particles >5 um (droplets) at… compared with saline (very low certainty).
1 finding from 1 review
Reduction in level of contamination by particles >5 um (droplets) at <2 m from patient's oral cavity · Dental patients undergoing aerosol-generating procedures (AGPs) and the dental healthcare providers treating them
Chlorhexidine (CHX) led to lower reduction in level of contamination by particles >5 um (droplets) at… compared with saline; GRADE not reported.
2 findings from 1 review
MD -668.4 [-1044.45, -292.35]
1 study · 20 participants
GRADE not reported
MD -21.33 [-36.8, -5.86]
1 study · 12 participants
Very low
Presence of dry socket · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
1 finding from 1 review
Reduction in wound size · people with acute and chronic wounds
It is very uncertain whether tap water changes reduction in wound size compared with normal saline (very low certainty).
1 finding from 1 review
Healing rate · people with acute and chronic wounds
1 finding from 1 review
Cost analysis · people with acute and chronic wounds
1 finding from 1 review